Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2026-02-03 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于与Nizhpharm签署许可及分销协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a licensing and distribution agreement between Shenzhen Microchip Biotechnology Co., Ltd. and Nizhpharm. It details the terms of the agreement, the parties involved, the scope of the license, payment terms, and potential risks. There is no financial data, no report attached or referenced as being published, and no indication of a regulatory filing or certification. The content is a corporate announcement about a business transaction (licensing agreement) rather than a financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to a significant business agreement impacting the company's commercial activities and potential revenue streams.
2026-02-03 Chinese
关于持股5%以上股东部分被冻结股份已解冻的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the unfreezing of shares held by a shareholder who previously had shares frozen. It details the number of shares unfrozen, the dates, and the shareholder involved. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. This fits the category of a Major Shareholding Notification, as it concerns changes in significant share ownership status (shares being unfrozen).
2026-01-30 Chinese
关于公司关联方拟参与认购向特定对象发行股票涉及关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding a related party transaction involving a proposed subscription to a private placement of shares by a related party (Nord Fund Management Co., Ltd.). It details the nature of the related party relationship, the approval process by the board and independent directors, the pricing basis, and the expected impact on the company. The document is a formal disclosure about a capital raising event involving related parties, specifically a private placement of shares to a specific investor group including a related party. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is an announcement about a capital/financing update related to share issuance and related party transactions. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 2870 characters, which is consistent with an announcement rather than a full report.
2026-01-29 Chinese
2025年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a performance forecast announcement for the fiscal year 2025, providing estimated revenue and profit figures before the official audited annual report is released. It explicitly states that the financial data are preliminary and unaudited, and that the final audited data will be disclosed in the formal 2025 annual report. The document length is short (1048 characters), and it serves as a forward-looking earnings preview rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, rather than a full Annual Report (10-K). FY 2025
2026-01-26 Chinese
关于“微芯转债”预计满足赎回条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the expected triggering of conditional redemption clauses for its convertible bonds (referred to as '微芯转债'). It details the bond issuance, redemption terms, and the conditions under which the company may redeem the bonds early. The document references regulatory guidelines from the Shanghai Stock Exchange and provides risk warnings and contact information. It does not contain financial statements, audit results, or detailed financial performance data. Instead, it is an update on financing instruments and potential redemption actions related to convertible bonds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2468 characters, which is consistent with an announcement rather than a full report.
2026-01-22 Chinese
关于2026年度日常关联交易额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the expected daily related-party transaction limits for the year 2026. It details the nature, amounts, and approval procedures of these related-party transactions, including information about the related parties and the company's internal approval process. The document is a regulatory announcement about anticipated related-party transactions, not a financial report or audit. It does not contain financial statements or detailed financial analysis but rather discloses corporate governance and compliance information related to related-party transactions. This fits the category of a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Interim Report, or Capital Update.
2026-01-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.